Chronic Myeloid Leukaemia (CML)

Management of CML.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
HaematologyOncology

Clinical Guidelines

ESMO Clinical Practice Guideline: Chronic Myeloid Leukaemia
National
Guideline on the diagnosis and management of chronic myeloid leukaemia
National
NICE guideline [TA70]
National
NICE Technology Appraisal Guidance [TA425]: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
National
NICE Technology Appraisal Guidance [TA70]: Guidance on the use of imatinib for chronic myeloid leukaemia
National
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Local
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Local
Guideline on the diagnosis and management of chronic myeloid leukaemia
Local
NICE technology appraisal guidance [TA425]: Bosutinib for previously treated chronic myeloid leukaemia
Local